We assign a fundamental rating of 5 out of 10 to ORGO. ORGO was compared to 525 industry peers in the Biotechnology industry. ORGO has only an average score on both its financial health and profitability. ORGO has a decent growth rate and is not valued too expensively.

Quickly go to:

1. Profitability

2. Health

3. Growth

4. Valuation

5. Dividend

1. Profitability

1.1 Basic Checks

In the past year ORGO was profitable.
In the past year ORGO has reported a negative cash flow from operations.
Of the past 5 years ORGO 4 years were profitable.
Each year in the past 5 years ORGO had a positive operating cash flow.

1.2 Ratios

With an excellent Return On Assets value of -2.63%, ORGO belongs to the best of the industry, outperforming 87.43% of the companies in the same industry.
With an excellent Return On Equity value of -3.47%, ORGO belongs to the best of the industry, outperforming 89.14% of the companies in the same industry.
ORGO's Return On Invested Capital of 0.16% is amongst the best of the industry. ORGO outperforms 88.76% of its industry peers.
ORGO had an Average Return On Invested Capital over the past 3 years of 3.79%. This is significantly below the industry average of 18.07%.

		Industry Rank	Sector Rank
ROA	-2.63%
ROE	-3.47%
ROIC	0.16%

ROA(3y)1.45%

ROA(5y)6.32%

ROE(3y)2.46%

ROE(5y)11.67%

ROIC(3y)3.79%

ROIC(5y)7.32%

1.3 Margins

ORGO has a Operating Margin of 0.18%. This is amongst the best in the industry. ORGO outperforms 88.76% of its industry peers.
ORGO's Operating Margin has declined in the last couple of years.
ORGO has a Gross Margin of 74.49%. This is amongst the best in the industry. ORGO outperforms 83.43% of its industry peers.
ORGO's Gross Margin has been stable in the last couple of years.

		Industry Rank	Sector Rank
OM	0.18%
PM (TTM)	N/A
GM	74.49%

OM growth 3Y-34.07%

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.17%

GM growth 5Y1.4%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), ORGO is destroying value.
The number of shares outstanding for ORGO has been reduced compared to 1 year ago.
ORGO has more shares outstanding than it did 5 years ago.
The debt/assets ratio for ORGO has been reduced compared to a year ago.

2.2 Solvency

ORGO has an Altman-Z score of 3.69. This indicates that ORGO is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of ORGO (3.69) is better than 70.48% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that ORGO is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.01, ORGO is in line with its industry, outperforming 46.67% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	0.01
Debt/FCF	N/A
Altman-Z	3.69

ROIC/WACC0.02

WACC9.11%

2.3 Liquidity

ORGO has a Current Ratio of 3.32. This indicates that ORGO is financially healthy and has no problem in meeting its short term obligations.
ORGO has a worse Current ratio (3.32) than 60.19% of its industry peers.
ORGO has a Quick Ratio of 2.88. This indicates that ORGO is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.88, ORGO is doing worse than 63.62% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	3.32
Quick Ratio	2.88

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for ORGO have decreased strongly by -90.91% in the last year.
ORGO shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -37.90% yearly.
ORGO shows a small growth in Revenue. In the last year, the Revenue has grown by 2.24%.
Measured over the past years, ORGO shows a quite strong growth in Revenue. The Revenue has been growing by 13.05% on average per year.

EPS 1Y (TTM)-90.91%

EPS 3Y-37.9%

EPS 5YN/A

EPS Q2Q%66.67%

Revenue 1Y (TTM)2.24%

Revenue growth 3Y0.98%

Revenue growth 5Y13.05%

Sales Q2Q%30.98%

3.2 Future

Based on estimates for the next years, ORGO will show a very strong growth in Earnings Per Share. The EPS will grow by 29.27% on average per year.
Based on estimates for the next years, ORGO will show a quite strong growth in Revenue. The Revenue will grow by 8.70% on average per year.

EPS Next Y-58%

EPS Next 2Y-6.73%

EPS Next 3Y29.27%

EPS Next 5YN/A

Revenue Next Year9.76%

Revenue Next 2Y8.03%

Revenue Next 3Y8.7%

Revenue Next 5YN/A

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

ORGO is valuated quite expensively with a Price/Earnings ratio of 395.00.
88.95% of the companies in the same industry are more expensive than ORGO, based on the Price/Earnings ratio.
ORGO is valuated expensively when we compare the Price/Earnings ratio to 27.25, which is the current average of the S&P500 Index.
ORGO is valuated quite expensively with a Price/Forward Earnings ratio of 26.71.
ORGO's Price/Forward Earnings ratio is rather cheap when compared to the industry. ORGO is cheaper than 92.19% of the companies in the same industry.
ORGO's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 25.98.

		Industry Rank	Sector Rank
PE	395
Fwd PE	26.71

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, ORGO is valued cheaper than 93.71% of the companies in the same industry.

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	22.95

4.3 Compensation for Growth

The decent profitability rating of ORGO may justify a higher PE ratio.
A more expensive valuation may be justified as ORGO's earnings are expected to grow with 29.27% in the coming years.